Clinical Trial Detail

NCT ID NCT03771820
Title Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NanoCarrier Co., Ltd
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

NC-6004 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.